Granules India cash flow

Latest FY26

Cash from operations: ₹793cr−8.5% on FY25
Capital spending: ₹558cr−2.4% on FY25
Free cash flow: ₹235cr−20.3% on FY25
Cash from financing: ₹379cr−₹92.5 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	296	226	207	184
	—	4.9	0.0	0.0	0.0
	—	114	103	106	55.9
	—	−7.0	−3.7	−2.8	−4.5
	—	11.5	0.0	0.0	0.0
	—	0.0	0.0	0.3	1.3
	—	−11.7	4.5	−7.7	−9.2
	—	0.0	0.0	25.9	9.6
	—	−18.1	14.6	0.0	0.0
	—	−139	−20.6	−141	−135
	—	145	35.9	−30.7	−0.1
	—	18.8	−13.0	−71.0	16.1
	—	0.0	0.0	−3.9	109
	—	0.0	3.7	0.0	0.0
	—	−166	0.0	0.0	0.0
Cash from operating activities
	881	785	660	547	687
	—	248	350	82.5	227
	—	1,033	1,010	630	915
	—	240	144	190	176
	—	793	867	439	739
Cash from investing activities
	—	558	572	381	411
	—	3.5	0.0	1.7	0.2
	—	0.0	1.7	0.0	0.0
	—	31.7	0.0	0.0	0.0
	—	198	0.0	0.0	0.0
	—	5.6	3.6	2.8	5.1
	—	−57.5	−125	15.9	214
	—	−773	−691	−360	−191
Cash from financing activities
	—	302	5.0	3.2	2.8
	—	366	0.0	0.0	0.0
	—	0.0	0.0	0.0	311
	—	0.6	2,401	1,970	46.0
	—	111	2,341	1,816	93.1
	—	21.2	17.8	11.3	12.9
	—	120	103	103	53.3
	—	36.4	36.4	36.3	18.6
	—	0.0	0.0	0.0	−0.5
	—	379	−92.5	7.7	−440
	—	399	82.8	86.9	107
	—	12.4	2.2	2.6	−0.3
	—	412	85.0	89.5	107
	—	880	466	381	292
Reference items
	1,277	1,185	945	856	914
	22.7%	22.1%	21.1%	19.0%	20.3%
	235	235	295	58.8	328
	—	167	254	121	—
	₹9.49	₹9.49	₹11.90	₹2.37	₹13.24
	88.61×	—	—	—	—
	—	1.33×	1.73×	1.08×	1.43×
	—	240	144	190	176
	—	120	103	103	53.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GRANULES₹840.45

Granules India Ltd.

· Pharma & Health

₹ CrorePeersAUROPHARMA IPCALAB AARTIDRUGS ERIS INDGN EMCURE JUBLPHARMA CONCORDBIOMcap ₹20,826 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	184.5	207.3	225.5	296.1	—
+ Impairment Loss / (Reversal)	0.0	0.0	0.0	4.9	—
+ Finance Costs	55.9	105.8	103.2	114.4	—
+ Interest Income	-4.5	-2.8	-3.7	-7.0	—
+ Fair Value (Gains) / Losses	0.0	0.0	0.0	11.5	—
+ Share-based Payments	1.3	0.3	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	-9.2	-7.7	4.5	-11.7	—
+ Other Non-cash Items	9.6	25.9	0.0	0.0	—
+ Other Reconciling Items	0.0	0.0	14.6	-18.1	—
Changes in Working Capital
+ Inventories	-135.5	-140.7	-20.6	-139.4	—
+ Trade Receivables — Current	-0.1	-30.7	35.9	144.6	—
+ Other Current Assets	16.1	-71.0	-13.0	18.8	—
+ Trade Payables — Current	109.2	-3.9	0.0	0.0	—
+ Trade Payables — Non-current	0.0	0.0	3.7	0.0	—
+ Other Current Liabilities	0.0	0.0	0.0	-165.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	687.2	547.2	660.2	785.0	880.9
+ Total Adjustments (incl. Working Capital)	227.4	82.5	350.2	248.5	—
Cash from Operations (pre-tax)	914.6	629.7	1,010.3	1,033.5	—
+ Income Taxes Paid	175.8	190.3	143.8	240.2	—
Cash from Operating Activities	738.7	439.4	866.6	793.3	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	410.7	380.6	571.7	558.2	—
+ Disp of Fixed Assets	0.2	1.7	0.0	3.5	—
+ Disp of Investment Property	0.0	0.0	1.7	0.0	—
+ Sale of Investments (Equity / Debt)	0.0	0.0	0.0	31.7	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	0.0	198.3	—
+ Interest Received — Investing	5.1	2.8	3.6	5.6	—
+ Other Inflows / (Outflows) — Investing	214.0	15.9	-124.9	-57.5	—
Cash from Investing Activities	-191.4	-360.2	-691.3	-773.2	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	2.8	3.2	5.0	301.9	—
+ Proceeds from Other Equity Instruments	0.0	0.0	0.0	365.6	—
+ Buyback / Redemption of Own Shares	310.7	0.0	0.0	0.0	—
+ Proceeds from Borrowings	46.0	1,970.5	2,400.9	0.6	—
+ Repayment of Borrowings	93.1	1,815.7	2,340.8	110.9	—
+ Payment of Lease Liabilities	12.9	11.3	17.8	21.2	—
+ Interest Paid	53.3	102.7	103.5	120.4	—
+ Dividends Paid	18.6	36.3	36.4	36.4	—
+ Other Inflows / (Outflows) — Financing	-0.5	0.0	0.0	0.0	—
Cash from Financing Activities	-440.3	7.7	-92.5	379.3	—
Net Changes in Cash (pre-FX)	107.1	86.9	82.8	399.3	—
+ Effect of FX Rate Changes on Cash	-0.3	2.6	2.2	12.4	—
Net Changes in Cash	106.8	89.5	85.0	411.7	—
Closing Cash	291.6	381.1	466.1	880.2	—
Reference Items
EBITDA	913.8	856.0	945.2	1,185.1	1,277.3
EBITDA Margin %	20.25	18.99	21.09	22.09	22.68
Free Cash Flow (CFO − Capex)	328.1	58.8	294.9	235.0	235.0
Free Cash Flow to Equity	—	120.8	254.0	167.0	—
Free Cash Flow per Basic Share	13.24	2.37	11.90	9.49	9.49
Price to Free Cash Flow	—	—	—	—	88.61
Cash Flow to Net Income	1.43	1.08	1.73	1.33	—
Cash Paid for Taxes	175.8	190.3	143.8	240.2	—
Cash Paid for Interest	53.3	102.7	103.5	120.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.